US5034391A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Piperazinylalkyl-3(2H)-pyridazinones and the use thereof as agents lowering blood pressure
Assignee: Cl Pharma AG
•
Filing: 1989-11-30
•
Granted: 1991-07-23
•
Expires: 2009-11-30
Abstract
Abstract The invention relates to new piperazinylalkyl-3(2H)-pyridazinones of the formula ##STR1## in which the radicals R 1 represents hydrogen, phenyl, benzyl, or (C 1 -C 6 )-alkyl which is unsubstituted or substituted one or more times by hydroxyl, piperidine, morpholine or by a group NR 4 R 5 in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, (C 1 -C 6 )-alkoxy or (C 1 -C 6 )-alkyl, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen, (C 1 -C 4 )-alkyl, phenyl, benzyl or phenylethyl, B represents (C 1 -C 7 )-alkylene which is unsubstituted or substituted one or more times by hydroxyl, (C 1 -C 4 )-alkyl or by the group NR 4 R 5 and which can optionally be closed to form an alicyclic 4- to 7-membered ring, R 8 and R 9 , which can be identical or different, represent hydrogen or (C 1 -C 6 )-alkyl and Z represents phenyl, naphthyl, pyridyl or thiazolyl, each of which can be unsubstituted or substituted one or more times by (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, benzyloxy, trifluoromethyl, halogen, nitro, (C 3 -C 7 )-cycloalkoxy, (C 1 -C 4 )-alkylthio, trifluoromethylthio or by the group NR 4 R 5 , the pharmaceutically utilizable salts thereof, a process for the preparation thereof and the use thereof as medicament for the treatment of hypertension, cardiac insufficiency and disturbances of peripheral circulation.
Inventors
- 👤 Heinz Blaschke
- 👤 Heimo Stroissnig
- 👤 Harald Fellier
- 👤 Rita Enzenhofer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:29
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; A; A61; A61P; A61P9/00; A61P9/12; C07D237/00; C07D237/02; C07D237/06; C07D237/10; C07D237/22; C07D403/00; C07D403/02; C07D403/12
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
150 words
A piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR6## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1-C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
150 words
A piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR6## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1-C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
182 words
A pharmaceutical composition for the treatment of disturbances of peripheral circulation comprising a piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR7## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1 -C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof in an amount effective for the treatment of disturbances of peripheral circulation, in combination with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
182 words
A pharmaceutical composition for the treatment of disturbances of peripheral circulation comprising a piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR7## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1 -C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof in an amount effective for the treatment of disturbances of peripheral circulation, in combination with a pharmaceutically acceptable carrier.
Claim 5
Independent Claim
188 words
A method for the treatment of disturbances of peripheral circulation, which comprises administering to a patient an effective amount of a pharmaceutical composition for the treatment of such disturbances comprising a piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR8## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1 -C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.
Claim 6
Independent Claim
188 words
A method for the treatment of disturbances of peripheral circulation, which comprises administering to a patient an effective amount of a pharmaceutical composition for the treatment of such disturbances comprising a piperazinylalkyl-3(2H)-pyridazinone of the formula I ##STR8## in which R 1 represents hydrogen, C 1 -C 6 alkyl, which is unsubstituted or substituted by hydroxyl or by a group NR 4 R 5 , in which R 4 and R 5 can be identical or different and which represent hydrogen, methyl or ethyl, R 2 and R 3 represent hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, where at least one of the radicals R 2 or R 3 denotes hydrogen, R 6 represents hydrogen or C 1 -C 4 alkyl, B represents C 1 -C 6 alkylene, R 8 and R 9 represent hydrogen or C 1 -C 4 alkyl, and Z represents phenyl, which is unsubstituted or substituted one or two times by C 1 -C 6 alkoxy, C 1 -C 4 alkyl, trifluoromethyl, halogen or nitro or pyridyl-2 or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
DE1086238B
Cited
US3398151A
Cited
US4067982A
Cited
FR2261756A1
Cited
US4131678A
Cited
JPS5742679A
Cited
US4910201A
Cited
US4826845A
Cited
US4859672A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-22 | 1995-01-21 | 1995-07-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-22 | 1999-01-21 | 1999-07-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-22 | 2003-01-21 | 2003-07-23 | $7700.00 | Window Closed / Lapsed |